Skip to content

Diagnostic value of human cysteine protease inhibitor S (CST4) in gastrointestinal cancer

Diagnostic value of human cysteine protease inhibitor S (CST4) in gastrointestinal cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018806
Enrollment
Unknown
Registered
2018-10-10
Start date
2019-02-09
Completion date
Unknown
Last updated
2018-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastrointestinal cancer

Interventions

Gold Standard:Pathological results, digestive endoscopy results
cysteine&#32
(CST4)

Sponsors

Changhai Hospital of Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Diagnostic value of serum CST4 in esophageal and gastric cancer(Simultaneously satisfy the three conditions) (1) aged 40 years and older; (2) Clinical suspicion of esophageal cancer or gastric cancer population, or a Physical examination population; (3) informed consent. 2. Diagnostic value of serum CST4 in colorectal cancer(Simultaneously satisfy the three conditions) (1) aged 40 years and older; (2) Clinical suspicion of colorectal cancer population, or Physical examination population; (3) informed consent.

Exclusion criteria

Exclusion criteria: 1. Diagnostic value of serum CST4 in esophageal and gastric cancer(Any of the following were excluded) (1) Not suitable for gastroscopy. (2) History of esophageal or stomach,colorectal surgery. (3) Those who are taking anticoagulants such as aspirin, clopidogrel, warfarin, or have coagulation disorders. (4) Severe cardiac, hepatic and renal insufficiency, or Severe mental disorders, or the researchers considered it inappropriate to participate in the study. 2. Diagnostic value of serum CST4 in colorectal cancer (1) Not suitable for Colonoscopy; (2) History of esophageal or stomach,colorectal surgery; (3) Those who are taking anticoagulants such as aspirin, clopidogrel, warfarin, or have coagulation disorders; (4) Severe cardiac, hepatic and renal insufficiency, or Severe mental disorders, or the researchers considered it inappropriate to participate in the study.

Design outcomes

Primary

MeasureTime frame
CST4;

Countries

China

Contacts

Public ContactLuowei Wang

Changhai Hospital of Shanghai

wangluoweimd@126.com+86 13901833088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026